TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Capstone Therapeutics ( (CAPS) ).
On November 18, 2025, Capstone Holding Corp. held its annual stockholders meeting where several key proposals were voted upon. The meeting, which had a quorum with 74.78% of votes represented, resulted in the election of two directors, the ratification of GBQ Partners LLC as the independent auditor, and the approval of the company’s reincorporation from Delaware to Nevada. Additionally, the 2025 Stock Incentive Plan was adopted, and executive compensation was approved to be reviewed every three years. These decisions are likely to impact the company’s governance and operational structure moving forward.
The most recent analyst rating on (CAPS) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Capstone Therapeutics stock, see the CAPS Stock Forecast page.
Spark’s Take on CAPS Stock
According to Spark, TipRanks’ AI Analyst, CAPS is a Neutral.
Capstone Therapeutics is facing significant financial instability with declining revenue, negative equity, and poor valuation metrics. The technical analysis indicates bearish trends, further compounding the financial challenges. The lack of earnings call data and corporate events leaves no room for positive catalysts, resulting in a low overall stock score.
To see Spark’s full report on CAPS stock, click here.
More about Capstone Therapeutics
Average Trading Volume: 2,567,620
Technical Sentiment Signal: Sell
Current Market Cap: $6.21M
Find detailed analytics on CAPS stock on TipRanks’ Stock Analysis page.